Skip to main content

Table 1 Demographic features of different cohorts

From: Lipocalin 2 links inflammation and ankylosis in the clinical overlap of inflammatory bowel disease (IBD) and ankylosing spondylitis (AS)

 AS aloneAS-IBDMBPIBDHC
N (male/female)462 (350/112)57 (44/13)52 (26/26)85 (85/0)158 (106/52)
HLA-B27 positivity78% (357/456)56% (32/57)0% (0/52)N/A0% (0/158)
CRP (mg/L)13.9 ± 21.115.4 ± 17.32.13 ± 2.8N/AN/A
ESR (mm/hour)13.5 ± 15.614.4 ± 17.26.2 ± 4.9N/AN/A
BASDAI4.8 ± 2.54.5 ± 2.64.8 ± 2N/AN/A
Biologics*43% (200/462)74% (42/57)N/AN/AN/A
Disease duration (years)2–622–53N/AN/AN/A
  1. *Biologics include infliximab, adalimumab, golimumab, and etanercept